Novartis agreed to acquire a Synnovation unit and pay $2 billion upfront to secure SNV4818, a next‑generation PI3Kα inhibitor that selectively targets mutant PI3Kα. The asset, in early clinical testing, is positioned as a tolerability‑improved alternative to existing PI3Kα drugs such as alpelisib. The deal consolidates Novartis’ oncology portfolio and reflects industry pressure to produce mutant‑selective inhibitors that maintain efficacy while reducing hyperglycemia and other class toxicities. Synnovation’s program remains in early trials with a primary completion date in 2027; Novartis cited potential to use the drug earlier in treatment lines and in combinations. Investors and competitors—including Lilly and Roche—have been advancing similar next‑gen PI3K programs, making this acquisition a defensive and strategic expansion for Novartis in hormone‑receptor positive, PIK3CA‑mutant breast cancer.